Browse by Hotbed/Location
Filter News
Found 701,347 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace. -
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Takeda plans to cut about 186 staff members across Massachusetts, beginning in early July. -
Weeks after announcing a CEO shake-up and slightly decreased Q1 revenues, BMS plans to cut 48 staff members from its Princeton, NJ, facility. -
Legend Biotech Corporation Announces Pricing of Registered Direct Offering of $350 Million of American Depositary Shares
5/8/2023
Legend Biotech Corporation today announced that it has agreed to sell 5,468,750 American Depositary Shares (“ADSs”), each representing two ordinary shares of the Company, at a price of $64.00 per ADS, in a registered direct offering.
-
Incyte Strengthens Research & Development Efforts Appointing Pablo J. Cagnoni, M.D. to New Leadership Role
5/8/2023
Dr. Cagnoni joins Incyte’s Executive Team as President and Head of Research & Development.
-
NLS Pharmaceutics Appoints Keith Harrison Dewedoff as Interim Chief Financial Officer
5/8/2023
NLS Pharmaceutics Ltd. today announced that Keith Harrison Dewedoff has been appointed to the position of Interim Chief Financial Officer.
-
Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line
5/8/2023
Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.
-
Solarea Bio Announces First Close of Series B Financing Round
5/8/2023
Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.
-
New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023
5/8/2023
INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.
-
Krystal Biotech Announces First Quarter 2023 Financial Results and Operational Highlights
5/8/2023
Krystal Biotech, Inc. today reported financial results and key operational progress updates for the first quarter ended March 31, 2023.
-
Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023
5/8/2023
Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer.
-
Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases
5/8/2023
Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.
-
Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
5/8/2023
Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).
-
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
5/8/2023
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).
-
Prelude Therapeutics Announces First Quarter 2023 Financial Results and Operations Update
5/8/2023
Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2023, and provided an update on recent clinical and development pipeline progress.
-
Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference
5/8/2023
Scholar Rock announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab.
-
BioXcel Therapeutics Reports First Quarter 2023 Financial Results and Recent Operational Highlights
5/8/2023
BioXcel Therapeutics, Inc. today announced its financial results for the first quarter ended March 31, 2023, and provided an update on key strategic initiatives.
-
Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]
5/8/2023
Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024.
-
Marker Therapeutics Appoints Monic Stuart, M.D., as Chief Medical Officer
5/8/2023
Marker Therapeutics, Inc. today announced the appointment of Monic Stuart, M.D., as its new Chief Medical Officer.